Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer
Prof Ferdinandos Skoulidis speaks to ecancer about the primary analysis of the phase III Krascendo 1 trial, which compared divarasib, a next-generation KRAS G12C inhibitor, with sotorasib or adagrasib in patients with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Among 338 patients, divarasib significantly improved progression-free survival, extending median progression-free survival from 5.7 to 9.8 months, and overall survival, increasing median overall survival from 12.0 to 17.7 months.
The objective response rate was also higher with divarasib, at 58.4% compared with 32.3% with sotorasib or adagrasib.
Divarasib demonstrated a manageable safety profile. Grade 3–4 treatment-related adverse events occurred in 24.6% of patients receiving divarasib compared with 34.5% in the control group.
Treatment discontinuations due to treatment-related adverse events were also less frequent with divarasib (4.8% vs 11.7%).
Prof Skoulidis says that these findings demonstrate significant improvements in progression-free and overall survival with divarasib compared with currently available KRAS G12C inhibitors, supporting its potential as a new standard of care for previously treated advanced KRAS G12C-mutated NSCLC.
Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer
Pembrolizumab plus chemotherapy shows pathological responses in resectable pleural mesothelioma
Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival
Tarlatamab improves brain metastases control and survival compared to chemo in SCLC
TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance
Cracking the code: Bispecific immunotherapy in small cell lung cancer
Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC
Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced